ERBB2 and ductal breast carcinoma in situ: Due to these positive adjuvant clinical trial and preclinical study results demonstrating delay of HER2-positive tumors following treatment with HER2 inhibitors, clinical cancer prevention trials have been developed to test trastuzumab or lapatinib in women with HER2-positive DCIS lesions.